Intake Duration Effects of Blackcurrant on Cardiovascular and Metabolic Responses

October 1, 2021 updated by: Mark Eilisabeth Willems, University of Chichester

Effects of Intake Duration of New Zealand Blackcurrant Extract on Physiological, Cardiovascular and Metabolic Responses at Rest and During Moderate-intensity Exercise in Healthy Males

Study will examine the metabolic, physiological and cardiovascular changes by intake of New Zealand blackcurrant extract at rest and during moderate-intensity treadmill walking in healthy males.

Study Overview

Status

Completed

Conditions

Detailed Description

The investigators will examine effects of acute intake, intermittent intake and chronic intake of New Zealand blackcurrant extract using indirect calorimetry and hemodynamic measurements.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Sussex
      • Chichester, West Sussex, United Kingdom, PO19 6PE
        • Mark Willems

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy
  • Non-smokers
  • Not taking any supplements
  • No known allergy to berries or berry products

Exclusion Criteria

  • Sedentary
  • Known high blood pressure
  • Smoking
  • On medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: new zealand blackcurrant extract
Capsules will be take daily or every other day.
Capsules taken daily or intermittent
Placebo Comparator: control
no capsules will be provided.
Capsules taken daily or intermittent

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in heart rate from baseline with acute intake, one week and two weeks intake of New Zealand blackcurrant extract
Time Frame: baseline, acute, one week and two weeks

The investigators will use a beat-to-beat blood pressure monitoring system (Portapres® Model 2, Finapres Medical Systems BV, Amsterdam, The Netherlands). The Portapres® is a beat-to-beat finger pressure analyser that allows the non-invasive continuous measurement of hemodynamic parameters. The finger cuff will be positioned around the same finger of the left hand for each testing. All measurements will be taken in rest and during moderate-intensity exercise.

Heart rate will be measured in beats/min.

baseline, acute, one week and two weeks
Changes in stroke volume from baseline with acute intake, one week and two weeks intake of New Zealand blackcurrant extract
Time Frame: baseline, acute, one week and two weeks

The investigators will use a beat-to-beat blood pressure monitoring system (Portapres® Model 2, Finapres Medical Systems BV, Amsterdam, The Netherlands). The Portapres® is a beat-to-beat finger pressure analyser that allows the non-invasive continuous measurement of hemodynamic parameters. The finger cuff will be positioned around the same finger of the left hand for each testing. All measurements will be taken in rest and during moderate-intensity exercise.

Stroke volume will be measured in mL.

baseline, acute, one week and two weeks
Changes in cardiac output from baseline with acute intake, one week and two weeks intake of New Zealand blackcurrant extract
Time Frame: baseline, acute, one week and two weeks

The investigators will use a beat-to-beat blood pressure monitoring system (Portapres® Model 2, Finapres Medical Systems BV, Amsterdam, The Netherlands). The Portapres® is a beat-to-beat finger pressure analyser that allows the non-invasive continuous measurement of hemodynamic parameters. The finger cuff will be positioned around the same finger of the left hand for each testing. All measurements will be taken in rest and during moderate-intensity exercise.

Cardiac output will be measured in L/min.

baseline, acute, one week and two weeks
Changes in blood pressure from baseline with acute intake, one week and two weeks intake of New Zealand blackcurrant extract
Time Frame: baseline, acute, one week and two weeks

The investigators will use a beat-to-beat blood pressure monitoring system (Portapres® Model 2, Finapres Medical Systems BV, Amsterdam, The Netherlands). The Portapres® is a beat-to-beat finger pressure analyser that allows the non-invasive continuous measurement of hemodynamic parameters. The finger cuff will be positioned around the same finger of the left hand for each testing. All measurements will be taken in rest and during moderate-intensity exercise.

Systolic, diastolic and mean arterial blood pressure will be measured in mmHg.

baseline, acute, one week and two weeks
Changes in total peripheral resistance from baseline with acute intake, one week and two weeks intake of New Zealand blackcurrant extract
Time Frame: baseline, acute, one week and two weeks

The investigators will use a beat-to-beat blood pressure monitoring system (Portapres® Model 2, Finapres Medical Systems BV, Amsterdam, The Netherlands). The Portapres® is a beat-to-beat finger pressure analyser that allows the non-invasive continuous measurement of hemodynamic parameters. The finger cuff will be positioned around the same finger of the left hand for each testing. All measurements will be taken in rest and during moderate-intensity exercise.

Total peripheral resistance will be measured in (mmHg·min)/L

baseline, acute, one week and two weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in oxygen consumption from baseline with acute intake, one week and two weeks intake.
Time Frame: baseline, acute, one week and two weeks

The investigators will use Douglas bags to collect expired air. Indirect calorimetry techniques will be used to measured oxygen consumption and carbon dioxide production and allow quantification of carbohydrate and fat oxidation in rest and during moderate-intensity treadmill walking.

Oxygen consumption will be measured in L/min

baseline, acute, one week and two weeks
Changes in carbon dioxide production from baseline with acute intake, one week and two weeks intake.
Time Frame: baseline, acute, one week and two weeks

The investigators will use Douglas bags to collect expired air. Indirect calorimetry techniques will be used to measured oxygen consumption and carbon dioxide production and allow quantification of carbohydrate and fat oxidation in rest and during moderate-intensity treadmill walking.

Carbon dioxide production will be measured in L/min.

baseline, acute, one week and two weeks
Changes in respiratory exchange ratio from baseline with acute intake, one week and two weeks intake.
Time Frame: baseline, acute, one week and two weeks

The investigators will use Douglas bags to collect expired air. Indirect calorimetry techniques will be used to measured oxygen consumption and carbon dioxide production and allow quantification of carbohydrate and fat oxidation in rest and during moderate-intensity treadmill walking.

Respiratory exchange ratio is unitless and calculated from the ratio of carbon dioxide production and oxygen consumption.

baseline, acute, one week and two weeks
Changes in carbohydrate oxidation from baseline with acute intake, one week and two weeks intake.
Time Frame: baseline, acute, one week and two weeks

The investigators will use Douglas bags to collect expired air. Indirect calorimetry techniques will be used to measured oxygen consumption and carbon dioxide production and allow quantification of carbohydrate and fat oxidation in rest and during moderate-intensity treadmill walking.

Carbohydrate oxidation is calculated using carbon dioxide production and oxygen consumption and expressed in g/min.

baseline, acute, one week and two weeks
Changes in fat oxidation from baseline with acute intake, one week and two weeks intake.
Time Frame: baseline, acute, one week and two weeks

The investigators will use Douglas bags to collect expired air. Indirect calorimetry techniques will be used to measured oxygen consumption and carbon dioxide production and allow quantification of carbohydrate and fat oxidation in rest and during moderate-intensity treadmill walking.

Fat oxidation is calculated using carbon dioxide production and oxygen consumption and expressed in g/min.

baseline, acute, one week and two weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mark E Willems, PhD, University of Chichester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2017

Primary Completion (Actual)

September 1, 2018

Study Completion (Actual)

September 1, 2018

Study Registration Dates

First Submitted

September 10, 2021

First Submitted That Met QC Criteria

October 1, 2021

First Posted (Actual)

October 4, 2021

Study Record Updates

Last Update Posted (Actual)

October 4, 2021

Last Update Submitted That Met QC Criteria

October 1, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • MW1718NZBCduration

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

But will be provide on request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on no Conditions

Clinical Trials on New Zealand blackcurrant extract

Subscribe